

Personalized Medicine of Cognitive Impairments Associated with Psychiatric Disorders

Guest Editor:

Prof. Dr. Takahiro Nemoto

Department of Neuropsychiatry,
Toho University Faculty of
Medicine, Tokyo, Japan

Deadline for manuscript
submissions:

15 March 2025

Message from the Guest Editor


Dear Colleagues,

Patients with psychosis show impairment over a broad spectrum of the cognitive domain, with deficits in attention, memory, executive function, and social cognition. Moreover, cognitive functioning is a predictor of social functioning, which includes such aspects as the ability to carry out activities of daily living, level of work functioning, and quality of interpersonal relations. Cognitive impairments also lead to difficulties for patients and families with nonpsychotic disorders. Complementary to the disease is the patient who may respond to certain treatments more optimally than other treatments. Understanding the underlying biology of disease and individual patient variation may improve care for patients, leading to more optimal outcomes. Both pharmacotherapy and psychological intervention are currently the main treatments for such cognitive impairments, and this special issue welcomes the latest research on pharmacotherapy and psychological intervention for all psychiatric disorders. Throughout this Special Issue, I look forward to facilitating active discussion on this topic.

Sincerely,

Prof. Dr. Takahiro Nemoto
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)